Drugs that contain Regorafenib
1. Stivarga patents expiration
STIVARGA's oppositions filed in EPO
STIVARGA Litigations
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7351834 | BAYER HLTHCARE | ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
Jun, 2022
(1 year, 9 months ago) | |
| US8637553 | BAYER HLTHCARE | Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions |
Feb, 2031
(6 years from now) | |
| US9957232 | BAYER HLTHCARE | 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide monohydrate |
Jul, 2032
(8 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8680124 | BAYER HLTHCARE | Treatment of cancers with acquired resistance to kit inhibitors |
Jun, 2030
(6 years from now) | |
| US9458107 | BAYER HLTHCARE | Process for the preparation of 4-{4-[({[4 chloro-3-(trifluoromethyl)-phenyl]amino}carbonyl)amino]-3-fluorphenoxy-N-ethylpyridie-carboxamide, its salts and monohydrate |
Apr, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-139) | Apr 27, 2024 |
| New Indication(I-744) | Apr 27, 2020 |
| Orphan Drug Exclusivity(ODE-44) | Feb 25, 2020 |
| Orphan Drug Exclusivity(ODE) | Feb 25, 2020 |
| New Chemical Entity Exclusivity(NCE) | Sep 27, 2017 |
| New Indication(I-667) | Feb 25, 2016 |
NCE-1 date: 27 September, 2016
Market Authorisation Date: 27 September, 2012
Treatment: Treatment of patients with gastrointestinal stromal tumor (gist), including but not limited to patients previously treated with imatinib and patients with gist having resistance to a kit tyrosine kina...
Dosage: TABLET;ORAL
How can I launch a generic of STIVARGA before it's drug patent expiration?
More Information on Dosage
STIVARGA family patents
